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Genetic Counseling and Prenatal Diagnosis for
mtDNA Disease
To the Editor:
Over the last decade, clinicians have seen an increasing
number of patients who have been diagnosed with
mtDNA disease (Chinnery and Turnbull 1997b). As a
consequence, clinicians also have seen more and more
women of childbearing age carrying a pathogenic
mtDNA mutation who seek advice about the potential
risks to future offspring (Chinnery and Turnbull 1997a).
With this trend in mind, the recent editorial by Poulton
et al. (1998) was timely, tackling the difficult but in-
triguing problem of the origin, segregation, and inher-
itance of heteroplasmic mtDNA mutations. The authors
placed particular emphasis on the transmission of path-
ogenic mutations, and, on the basis of their interpreta-
tion of mechanisms, they suggested an approach to the
counseling for and prenatal diagnosis of mtDNA disease
that could be used in clinical practice. However, because
our understanding of the mechanisms governing these
processes is rudimentary at best, caution must be used
when counseling families with mtDNA disease.
At the most general level, two processes contribute to
the marked intrafamilial variation of genotype and phe-
notype that is the hallmark of mtDNA disease (Chinnery
and Turnbull 1997b). The first process occurs during the
early embryonic development of a female. Between the
formation of the zygote and the maturation of the oocyte
lineage, the cellular copy number of mtDNA is reduced
and then amplified. This results in a high level of vari-
ability in the level of mutated mtDNA that is transmitted
to the subsequent generation. Poulton et al. (1998) refer
to this process as the bottleneck, but whether the vari-
ability results from selection events (e.g., see Hauswirth
and Laipis 1985) or from random drift (Jenuth et al.
1996) is the subject of debate. In the second process,
further diversity is generated as mutated genomes dif-
ferentially replicate and segregate during histogenesis
and organ maturation (for a review, see Lightowlers et
al. 1997).
These two processes are of intense interest to those
scientists who seek to understand the mechanisms that
determine the inheritance of mtDNA. Not surprisingly,
their importance also has been recognized by clinicians
who counsel women at risk of transmitting hetero-
plasmic pathogenic mtDNA mutations. At present, un-
fortunately, very little guidance can be offered to these
women. There are three possible approaches to resolving
the clinical problem: (1) application of our understand-
ing of the mitochondrial genetic bottleneck; (2) empirical
investigation of the relationship between the maternal
mutation load and the mutation load and clinical phe-
notypes among offspring; and (3) the use of prenatal
diagnostic tests.
Although our rudimentary understanding of the bot-
tleneck might be tempting to use when counseling pa-
tients, it is, in fact, of limited practical use at present.
There are a number of theoretical and experimental
problems that beset the bottleneck phenomenon. First,
differences in the number of mtDNA molecules and in
the number of cell divisions during germ-line develop-
ment may have a profound effect on the size of the
bottleneck, thus weakening any simple extrapolation of
data from animal studies to humans (Austin 1995; Stra-
chan and Lindsay 1997). Second, undefined differences
among embryos may result in bottlenecks of different
sizes (Herbert et al. 1995); there is no evidence of a
simple, one-size-fits-all bottleneck (Howell et al. 1992).
Finally, and perhaps most importantly, although math-
ematical models of the bottleneck can be used to predict
the range of possible levels of mutant mtDNA in an
offspring, the resulting range is so wide as to be of lim-
ited value in counseling. For the specific example de-
scribed by Poulton et al. (1998)—namely, a female with
21%mutant mtDNA in her blood—the 95% confidence
interval of the mutation load in her offspring is
0%–50%. Furthermore, even if prediction of the precise
level of mutant mtDNA in the blood of the offspring
was possible, the clinical outcome from a particular
mtDNA mutation load cannot be predicted with a high
level of confidence, at the present time (Chinnery et al.
1997). For example, even for the A8344G mutation,
there is considerable overlap between the levels of mu-
tant mtDNA detected in the blood of clinically affected
individuals and the levels in their unaffected relatives
(fig. 1). Thus, the complex and multisystem clinical phe-
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Figure 1 Percentage of mutant mtDNA in blood, for 72 indi-
viduals harboring the A3243G MERRF (myoclonic epilepsy with rag-
ged red fibers) mutation. For the details of data acquisition, see the
article by Chinnery et al. (1997).
notypes are difficult to predict on the simple basis of
blood levels of mutant mtDNA in an individual har-
boring an mtDNA mutation.
An alternative, more empirical approach would be to
study the outcome of pregnancy in a large number of
women with heteroplasmic mtDNA mutations, without
making any assumptions about the mechanism of the
bottleneck. Thus, even with the limitations of a retro-
spective multicenter study, the frequency of clinically af-
fected offspring born to womenwho harbor the A3243G
or the A8344G point mutation recently has been shown
to be related to the level of mutant mtDNA in the moth-
ers’ blood (Chinnery et al., in press). However, the re-
lationship clearly differed for the two pathogenic mu-
tations, which indicates significant differences in the
expression of the two mutations, for a given inherited
mutation load. Although the use of this retrospective
data to give precise estimates of the risks involved for a
particular female is premature, these observations un-
derscore the potential value of more-extensive longitu-
dinal, tissue-distribution, and, especially, prospective
analyses.
Finally, preimplantation testing of a chorionic villus
biopsy may prove useful for counseling; however, at
present, there is very little data to support its use. If the
level of mutant mtDNA is distributed evenly to all the
tissues of a developing embryo and if the mutation load
stays constant with time, then this technique may be
reliable (as may be the case for the T8993G/C point
mutations). However, it is already known that the level
of mutant mtDNA is not distributed evenly in most pa-
tients with mtDNA disease and that this differential seg-
regation probably occurs at the later stages of devel-
opment. Even subtle variations in tissue mutation load
may lead to a profound variation in the phenotype, and
sampling of a single cell or chorionic villus may not
reflect the load in clinically relevant organs such as the
brain. Further studies are needed to establish the value
of these potentially hazardous techniques in the coun-
seling of patients with mitochondrial disease.
The prevalence of pathogenic mtDNA defects is at
least 1/10,000 in the general population of northern Eu-
rope (Majamaa et al. 1998; P.F.C. and D.M.T., unpub-
lished data). Many of these individuals are women of
childbearing age who urgently need genetic counseling
and advice, with regard to both the prognosis for their
children and the risk of disease in subsequent offspring.
Poulton et al. (1998) have highlighted some of the dif-
ficulties encountered in counseling these patients, and
their discussion has given us much food for thought.
However, their recommended acceptance of a proposed
simple bottleneck model and its application to prenatal
mitochondrial diagnosis is premature.
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